首页> 外文期刊>Cellular and molecular biology >Her-2eu oncogene expression in Puerto Rican females with breast cancer.
【24h】

Her-2eu oncogene expression in Puerto Rican females with breast cancer.

机译:Her-2 / neu癌基因在波多黎各女性乳腺癌中的表达。

获取原文
获取原文并翻译 | 示例
           

摘要

Her-2eu belongs to the family of tyrosine kinase transmembrane proteins whose overexpression has been associated with a poor prognosis in patients with breast cancer. The product of this proto-oncogene is overexpressed in 25-30% of human breast cancer and is the target of selective immunotherapy. Concerned about the ethnic differences on the expression of this oncogene, we have evaluated 143 consecutive specimens of primary breast cancer diagnosed in San Pablo Hospital, Puerto Rico. The specimens were analyzed for Her-2eu expression using immunohistochemistry assays (Hercept test). We have related the expression of hormone receptor status, percent cells in S phase, DNA ploidy, tumor size, nodal status and menopausal state with the Her2eu expression. Out of 143 specimens, 28 overexpressed the Her-2eu (19.6%). Of the Her/2 negative 30/114 (26%) were estrogen receptor negative as compared to 9/27 (33%) (p = 0.464). The degree of aneuploidy was abnormal in 25/104 (24%) in the Her-2eu negative vs 11/27 (41%) p = 0.083. The percent cell in DNA synthesis was high in 16/77 (21%) in Her-2eu negative vs 4/15 (27%) p = 0.613. The tumor size was greater than 2 cm in 35/106 (33%) in Her-2eu negative vs 9/23 (39%) p = 0.575. In the progesterone specimens negative for Her2, 44/114 (39%) were Her2eu negative vs 15/27 (56%) p = 0.108. No differences were seen regarding menopausal status, age and nuclear grading. A trend favoring abnormal aneuploidy in Her2eu positive was seen. Nodal involvement was significantly associated with Her2eu overexpression. (p = 0.037). Although the incidence of Her2 overexpression found in this database was somewhat lower than the one reported in the literature, this might also be due to the small cohort examined or to the technique utilized.
机译:Her-2 / neu属于酪氨酸激酶跨膜蛋白家族,其过表达与乳腺癌患者的不良预后有关。这种原癌基因的产物在25%至30%的人类乳腺癌中过表达,是选择性免疫疗法的目标。考虑到该癌基因表达的种族差异,我们评估了在波多黎各圣巴勃罗医院诊断出的143例连续的原发性乳腺癌标本。使用免疫组织化学测定法(Hercept测试)分析样本的Her-2 / neu表达。我们已经将激素受体状态,S期细胞百分比,DNA倍性,肿瘤大小,淋巴结状态和绝经状态的表达与Her2 / neu表达相关。在143个样本中,有28个过度表达了Her-2 / neu(19.6%)。在Her / 2阴性者中,雌激素受体阴性的30/114(26%)为9/27(33%)(p = 0.464)。 Her-2 / neu阴性的非整倍性程度异常在25/104(24%),而11/27(41%)p = 0.083。 DNA合成中的百分比细胞在Her-2 / neu阴性中为16/77(21%),而在4/15(27%)中p = 0.613。在Her-2 / neu阴性的35/106(33%)中,肿瘤大小大于2 cm,而在9/23(39%)中,p = 0.575。在Her2阴性的孕酮样本中,44/114(39%)的Her2 / neu阴性与15/27(56%)的p = 0.108。在绝经状态,年龄和核分级方面没有发现差异。在Her2 / neu阳性中发现了有利于异常非整倍性的趋势。淋巴结转移与Her2 / neu过表达显着相关。 (p = 0.037)。尽管在此数据库中发现的Her2过表达的发生率比文献中报道的发生率低一些,但这也可能是由于检查的队列较小或使用的技术所致。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号